New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
09:18 EDTBSDMBSD Medical initates Phase I/II study using hyperthermia
BSD Medical reported initiation of a Phase I/II study using hyperthermia, delivered using either the BSD-2000 Hyperthermia System or the BSD-500 Hyperthermia System, combined with proton radiotherapy to treat patients with unresectable soft tissue sarcoma. The clinical study has been designed in joint cooperation with Kantonsspital Aarau, Paul Scherrer Institute, Villigen, Uniklinik Balgrist, Zurich, and University Hospital, Zurich. The Phase I/II study will include 28 adult patients with primary and unresectable soft tissue sarcomas of extremities and trunk. The trial has been registered at and is open for patient enrollment. The company said, "Consequently, for unresectable primary and recurrent soft tissue sarcomas, the thermoradiobiological and physical advantages of hyperthermia and proton beam radiotherapy could be expected to produce a greater tumour regression, higher tumour downstaging, superior resectability with organ and limb preservation and improved survival outcome without significant treatment related morbidity."
News For BSDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
06:44 EDTBSDMBSD Medical intends to exit hyperthermia business in 2015
BSD Medical announced its strategic plans and initial revenue targets for the upcoming three-year period. CEO Clint Carnell said, "The company’s dual focus on hyperthermia and microwave ablation since 2010 has diluted our ability to effectively market, sell, and invest in the commercial success of both businesses. Success in Life Sciences requires an evidence-based approach coupled with top line sales growth through customer adoption – and in order for BSD to be successful, we need to focus on microwave ablation. In 2015, we intend to focus on successfully exiting our hyperthermia business, and implementing a strategic plan that is exclusively focused on our highest return opportunity – the disruptive, high-growth microwave ablation market." Looking ahead, the company targets microwave ablation revenue of $3.5M-$5M in 2015, and a YoY growth of 100% in each consecutive year beginning in calendar year 2016. The company targets microwave ablation gross margin for the three year period of 65%-75%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use